PRL and neoplasm: There are a few therapeutic alternatives for DA-resistant prolactinomas, E. Sosa-Eroza reported that addition of octreotide to ongoing cabergoline treatment resulted in significant reductions in PRL levels and tumor volume in 2 out of 5 patients (41).